Endocan as a predictor of increased cardiovascular risk during the menopausal transition period-Reference-Cited by-同舟云学术

Endocan as a predictor of increased cardiovascular risk during the menopausal transition period

Published:2020-04-08 Issue:6 Volume:301 Page:1553-1560
ISSN:0932-0067
Container-title:Archives of Gynecology and Obstetrics
language:en
Short-container-title:Arch Gynecol Obstet

Author:

Yıldız Şükrü^ORCID,Kaya Cihan^ORCID,Gedikbaşı Asuman,Cengiz Hüseyin^ORCID,Alay İsmail^ORCID,Öztürk Emine^ORCID,Tunca Aysun Fendal^ORCID,Yaşar Levent^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Obstetrics and Gynaecology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00404-020-05520-7.pdf

Reference41 articles.

1. Lloyd-Jones D, Adams RJ, Brown TM et al (2010) Heart disease and stroke statistics-2010 update: a report from the American Heart Association. Circulation 121:e46–e215

2. Sowers M, Zheng H, Tomey K et al (2007) Changes in body composition in women over six years at midlife: ovarian and chronological aging. J Clin Endocrinol Metab 92:895–901

3. Matthews KA, Meilahn E, Kuller LH et al (1989) Menopause and risk factors for coronary heart disease. N Engl J Med 321:641–646

4. Sarrazin S, Adam E, Lyon M et al (2006) Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 1765:25–37

5. Kali A, Shetty KS (2014) Endocan: a novel circulating proteoglycan. Indian J Pharmacol 46:579–583

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biliverdin modulates the long non-coding RNA H19/microRNA-181b-5p/endothelial cell specific molecule 1 axis to alleviate cerebral ischemia reperfusion injury;Biomedicine & Pharmacotherapy;2022-09

2. Endocan: a new marker of endothelial function;Current Opinion in Cardiology;2021-04-29